Debra Silberg
Direktor/Vorstandsmitglied bei Ellodi Pharmaceuticals
Profil
Debra Silberg is currently working as a Director at Ellodi Pharmaceuticals since 2023.
Prior to this, she worked as VP-Clinical Development at Shire Plc and as Chief Medical Officer at Finch Therapeutics Group, Inc. She completed her undergraduate degree from the University of Michigan and holds a doctorate degree from D'Amore-Mckim School of Business and The Wayne State University School of Medicine.
Aktive Positionen von Debra Silberg
| Unternehmen | Position | Beginn |
|---|---|---|
Ellodi Pharmaceuticals
 Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | Direktor/Vorstandsmitglied | 27.02.2023 |
Ehemalige bekannte Positionen von Debra Silberg
| Unternehmen | Position | Ende |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
| SHIRE | Corporate Officer/Principal | - |
Ausbildung von Debra Silberg
| University of Michigan | Undergraduate Degree |
| D'Amore-Mckim School of Business | Doctorate Degree |
| The Wayne State University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Private Unternehmen | 2 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Ellodi Pharmaceuticals
Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | Health Technology |
